[HTML][HTML] Incidence and predictive factors for infectious disease after rituximab therapy in kidney‐transplant patients
N Kamar, O Milioto, B Puissant‐Lubrano… - American Journal of …, 2010 - Elsevier
Rituximab off‐label use includes organ transplantation. We review the occurrence of
infectious disease and its outcome after rituximab therapy. Between April 2004 and August
2008, 77 kidney‐transplant patients received rituximab therapy [2–8 courses (median 4) of
375 mg/m 2 each] for various reasons. Their results were compared with a control group (n=
902) who had received no rituximab. After a median follow‐up of 16.5 (1–55) months for
rituximab patients and 60.9 (1.25–142.7) months for control patients, the incidence of …
infectious disease and its outcome after rituximab therapy. Between April 2004 and August
2008, 77 kidney‐transplant patients received rituximab therapy [2–8 courses (median 4) of
375 mg/m 2 each] for various reasons. Their results were compared with a control group (n=
902) who had received no rituximab. After a median follow‐up of 16.5 (1–55) months for
rituximab patients and 60.9 (1.25–142.7) months for control patients, the incidence of …
